<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737826</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00046473</org_study_id>
    <nct_id>NCT02737826</nct_id>
  </id_info>
  <brief_title>Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper</brief_title>
  <official_title>Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic opioid therapy for pain can be associated with significant risks, and a significant&#xD;
      number of patients maintained on chronic opioids have continued pain and/or poor functioning.&#xD;
      When patients need to or want to come off their opioid pain medications, there is little to&#xD;
      guide physicians as to how to best help them do so, and it is not known how patients do after&#xD;
      coming off opioid medications. The goals of this study are (1) to evaluate two medications in&#xD;
      assisting patients in coming off their opioid pain medications and (2) determining outcomes&#xD;
      after discontinuing opioids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">December 9, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Tolerate Buprenorphine Initiation</measure>
    <time_frame>8 hours post dose</time_frame>
    <description>For Phase I, the primary outcome measure is the percentage of patients who tolerate buprenorphine initiation within an 8-hour initiation period, as evidenced by a total score of 3 points when summing the following measures (1) moderate-good level of pain control (same or improved rating on a 0-10 visual analogue scale for pain) = 1 point, (2) mild to no withdrawal symptoms (≤10 on the Subjective Opioid Withdrawal Scale) = 1 point, and (3) willingness to continue to the stabilization and tapering phase of the study; &quot;yes&quot; = 1 point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Achieve Opioid Cessation</measure>
    <time_frame>8 weeks after stabilization at Week 10</time_frame>
    <description>For Phase II, the primary outcome measure will be number of participants opioid who achieve cessation 8 weeks after stabilization at Week 10, evidenced as a score of 3 points when summing the following measures: self-report of no opioid use = 1 point; prescription drug monitoring data showing no opioid prescriptions filled in past 30 days = 1 point; and confirmatory negative urine toxicology for a full panel of opioids = 1 point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieve Opioid Cessation Post-enrollment: 1 Month</measure>
    <time_frame>1 month post-enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Self-report: Brief Pain Inventory, Pain Catastrophizing Scale</measure>
    <time_frame>baseline, weekly during stabilization and taper</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Laboratory Testing: Mechanical, DNIC</measure>
    <time_frame>baseline, post-stabilization, follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Misuse Risk: Current Opioid Misuse Measure</measure>
    <time_frame>Baseline, post-stabilization, post-taper</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Function: PROMIS Physical Function Short Form (PROMIS SF 10)</measure>
    <time_frame>baseline, post-stabilization, post-taper</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep: Pittsburgh Sleep Quality Index</measure>
    <time_frame>baseline, post-stabilization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Withdrawal: Subjective Opioid Withdrawal Scale</measure>
    <time_frame>baseline, pre-induction, post-induction, post-stabilization, weekly during taper, post-taper</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Co-morbidity: Structured Clinical Interview (SCID)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Characteristics: Standard Demographic Information; Pain Diagnosis and History; Opioid History and Characteristics; Other Medications (Including Analgesics); Medical Co-morbidities</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Opioid Cessation Post-enrollment - 3 Months</measure>
    <time_frame>Post-enrollment - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Opioid Cessation Post-enrollment - 6 Months</measure>
    <time_frame>Post-enrollment - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Opioid Cessation Post-enrollment - 12 Months</measure>
    <time_frame>Post-enrollment - 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Opioid Pain Medication</condition>
  <arm_group>
    <arm_group_label>Phase - Buprenorphine Initiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. &quot;Buprenorphine tolerability&quot; will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - Gabapentin + Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - Placebo + Buprenorphine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - Buprenorphine taper</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine Initiation - Phase I</intervention_name>
    <description>In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.</description>
    <arm_group_label>Phase - Buprenorphine Initiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin + Buprenorphine - Phase II</intervention_name>
    <description>Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.</description>
    <arm_group_label>Phase II - Gabapentin + Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Buprenorphine - Phase II</intervention_name>
    <description>Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.</description>
    <arm_group_label>Phase II - Placebo + Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine taper - Phase II</intervention_name>
    <description>After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.</description>
    <arm_group_label>Phase II - Buprenorphine taper</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 70 years of age&#xD;
&#xD;
          -  Ability to speak and read in English&#xD;
&#xD;
          -  Currently taking chronic opioid therapy for pain for at least 6 months&#xD;
&#xD;
          -  On opioid dose of &gt;60mg and &lt;200mg oral morphine equivalents/day&#xD;
&#xD;
          -  Voluntarily seeking opioid discontinuation&#xD;
&#xD;
          -  Willing to attempt buprenorphine-assisted opioid discontinuation&#xD;
&#xD;
          -  Willing to be randomized to gabapentin or placebo&#xD;
&#xD;
          -  Have current physician who is actively prescribing opioids and who will be notified by&#xD;
             the research team of the patient's entry into the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous intolerance or allergy to buprenorphine or gabapentin&#xD;
&#xD;
          -  Diagnostic &amp; Statistical Manual -V criteria for substance use disorder currently or in&#xD;
             the past (other than nicotine)&#xD;
&#xD;
          -  Unstable medical or psychiatric condition that would preclude safe or meaningful&#xD;
             participation (e.g. traumatic brain injury; severe mental illness; severe cardiac,&#xD;
             renal, pulmonary, or liver disease)&#xD;
&#xD;
          -  Current use of illicit drugs&#xD;
&#xD;
          -  Maintenance on fentanyl or methadone&#xD;
&#xD;
          -  Current treatment with gabapentin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02737826/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I - Buprenorphine Initiation</title>
          <description>In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol using up to 16mg of buprenoprhine over an up to 8 hour induction window. &quot;Buprenorphine tolerability&quot; will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper.&#xD;
Buprenorphine - Phase I: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.</description>
        </group>
        <group group_id="P2">
          <title>Phase II - Gabapentin + Buprenorphine Taper</title>
          <description>Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period where buprenorphine will be titrated up as tolerated/needed to a maximum of 24 mg/day and gabapentin will be titrated up to 1600mg/day in 3 daily doses as tolerated. After the 2 week stabilization period, buprenorphine tapering will begin according to a tapering schedule that will last up to 8 weeks based on stabilizing buprenorphine dose.&#xD;
After the buprenorphine taper is complete, a 1 week taper of gabapentin will be provided.</description>
        </group>
        <group group_id="P3">
          <title>Phase II - Placebo + Buprenorphine Taper</title>
          <description>Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period where buprenorphine will be titrated up as tolerated/needed to a maximum of 24 mg/day and placebo will be titrated up to 1600mg/day in 3 daily doses as tolerated. After the 2 week stabilization period, buprenorphine tapering will begin according to a tapering schedule that will last up to 8 weeks based on stabilizing buprenorphine dose.&#xD;
After the buprenorphine taper is complete, a 1 week taper of placebo will be provided.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I - Buprenorphine Initiation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II - Randomization + Taper</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol. &quot;Buprenorphine tolerability&quot; will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper.&#xD;
Buprenorphine - Phase I: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.48" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Tolerate Buprenorphine Initiation</title>
        <description>For Phase I, the primary outcome measure is the percentage of patients who tolerate buprenorphine initiation within an 8-hour initiation period, as evidenced by a total score of 3 points when summing the following measures (1) moderate-good level of pain control (same or improved rating on a 0-10 visual analogue scale for pain) = 1 point, (2) mild to no withdrawal symptoms (≤10 on the Subjective Opioid Withdrawal Scale) = 1 point, and (3) willingness to continue to the stabilization and tapering phase of the study; &quot;yes&quot; = 1 point.</description>
        <time_frame>8 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I - Buprenorphine Initiation</title>
            <description>In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol. &quot;Buprenorphine tolerability&quot; will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper.&#xD;
Buprenorphine - Phase I: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Tolerate Buprenorphine Initiation</title>
          <description>For Phase I, the primary outcome measure is the percentage of patients who tolerate buprenorphine initiation within an 8-hour initiation period, as evidenced by a total score of 3 points when summing the following measures (1) moderate-good level of pain control (same or improved rating on a 0-10 visual analogue scale for pain) = 1 point, (2) mild to no withdrawal symptoms (≤10 on the Subjective Opioid Withdrawal Scale) = 1 point, and (3) willingness to continue to the stabilization and tapering phase of the study; &quot;yes&quot; = 1 point.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieve Opioid Cessation</title>
        <description>For Phase II, the primary outcome measure will be number of participants opioid who achieve cessation 8 weeks after stabilization at Week 10, evidenced as a score of 3 points when summing the following measures: self-report of no opioid use = 1 point; prescription drug monitoring data showing no opioid prescriptions filled in past 30 days = 1 point; and confirmatory negative urine toxicology for a full panel of opioids = 1 point.</description>
        <time_frame>8 weeks after stabilization at Week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase II - Gabapentin + Buprenorphine Taper</title>
            <description>Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.&#xD;
Buprenorphine - Phase I: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.&#xD;
Gabapentin - Phase II: Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.&#xD;
Placebo - Phase II: Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.</description>
          </group>
          <group group_id="O2">
            <title>Phase II - Placebo + Buprenorphine Taper</title>
            <description>Subjects who tolerate buprenorphine initiation in Phase I (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.&#xD;
Buprenorphine - Phase I: In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.&#xD;
Gabapentin - Phase II: Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.&#xD;
Placebo - Phase II: Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieve Opioid Cessation</title>
          <description>For Phase II, the primary outcome measure will be number of participants opioid who achieve cessation 8 weeks after stabilization at Week 10, evidenced as a score of 3 points when summing the following measures: self-report of no opioid use = 1 point; prescription drug monitoring data showing no opioid prescriptions filled in past 30 days = 1 point; and confirmatory negative urine toxicology for a full panel of opioids = 1 point.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieve Opioid Cessation Post-enrollment: 1 Month</title>
        <time_frame>1 month post-enrollment</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Self-report: Brief Pain Inventory, Pain Catastrophizing Scale</title>
        <time_frame>baseline, weekly during stabilization and taper</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Laboratory Testing: Mechanical, DNIC</title>
        <time_frame>baseline, post-stabilization, follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Misuse Risk: Current Opioid Misuse Measure</title>
        <time_frame>Baseline, post-stabilization, post-taper</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Function: PROMIS Physical Function Short Form (PROMIS SF 10)</title>
        <time_frame>baseline, post-stabilization, post-taper</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep: Pittsburgh Sleep Quality Index</title>
        <time_frame>baseline, post-stabilization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Withdrawal: Subjective Opioid Withdrawal Scale</title>
        <time_frame>baseline, pre-induction, post-induction, post-stabilization, weekly during taper, post-taper</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychiatric Co-morbidity: Structured Clinical Interview (SCID)</title>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Characteristics: Standard Demographic Information; Pain Diagnosis and History; Opioid History and Characteristics; Other Medications (Including Analgesics); Medical Co-morbidities</title>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Opioid Cessation Post-enrollment - 3 Months</title>
        <time_frame>Post-enrollment - 3 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Opioid Cessation Post-enrollment - 6 Months</title>
        <time_frame>Post-enrollment - 6 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Opioid Cessation Post-enrollment - 12 Months</title>
        <time_frame>Post-enrollment - 12 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I - Buprenorphine Initiation</title>
          <description>In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.</description>
        </group>
        <group group_id="E2">
          <title>Phase II - Gabapentin + Buprenorphine</title>
          <description>Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.</description>
        </group>
        <group group_id="E3">
          <title>Phase II - Gabapentin + Placebo</title>
          <description>Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.</description>
        </group>
        <group group_id="E4">
          <title>Phase II - Buprenorphine Taper</title>
          <description>After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sedation/sleepiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle twitching/spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kelly Barth</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-0686</phone>
      <email>stephen@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

